1h Free Analyst Time
The urea cycle disorder treatment market is forecasted to grow by USD 215.4 million during 2023-2028, accelerating at a CAGR of 3.2% during the forecast period. The report on the urea cycle disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of urea cycle disorder, rising geriatric patients, and rising focus on strategic initiatives.
The urea cycle disorder treatment market is segmented as below:
By Therapy
- Glycerol phenylbutyrate
- Sodium phenylbutyrate
- Amino acid supplements
- Sodium benzoate
- Others
By Route Of Administration
- Oral
- Injectables
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the urea cycle disorder treatment market covers the following areas:
- Urea cycle disorder treatment market sizing
- Urea cycle disorder treatment market forecast
- Urea cycle disorder treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global urea cycle disorder treatment market: Abbott Laboratories, Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Arcturus Therapeutics Holdings Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, CAMP4, Dipharma SA, Eurocept B.V., Horizon Therapeutics Plc, Immedica Pharma AB, Medunik USA, Nestle SA, Orpharma Pty Ltd., Reckitt Benckiser Group Plc, Recordati S.p.A, RELIEF THERAPEUTICS Holding SA, Swedish Orphan Biovitrum AB, Synlogic Inc., and Ultragenyx Pharmaceutical Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing growth potential in emerging economies."
According to the report, one of the major drivers for this market is the increasing prevalence of urea cycle disorder.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Acer Therapeutics Inc.
- Aeglea BioTherapeutics Inc.
- Arcturus Therapeutics Holdings Inc.
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- CAMP4
- Dipharma SA
- Eurocept B.V.
- Horizon Therapeutics Plc
- Immedica Pharma AB
- Medunik USA
- Nestle SA
- Orpharma Pty Ltd.
- Reckitt Benckiser Group Plc
- Recordati S.p.A
- RELIEF THERAPEUTICS Holding SA
- Swedish Orphan Biovitrum AB
- Synlogic Inc.
- Ultragenyx Pharmaceutical Inc.
